Colorectal Cancer Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)
1. Colorectal Cancer Market - Executive Summary
1.1. Introduction
1.2. Objectives
1.3. Key Findings
1.3.1. Market Size 2025 & 203: By Key Country (10MM)
1.3.2. Global Market Size 2025 & 2030: By Key Segment
1.3.3. Key Investments & Startup Analysis
1.4. Research Methodology
2. Understanding the Disease
2.1. Disease Overview
2.2. Classification
2.3. Signs and Symptoms
2.4. Risk Factors
2.5. Causes
2.6. Disease Biology & Digital Innovations
2.7. Stages & Staging System
2.8. Diagnostic Algorithm
2.9. Current Treatment Practices & Algorithm
2.10. Current Standard of Care and Treatment Gaps
2.11. Patient Demographics and Treatment Pathways
3. Guidelines
4. Unmet Needs
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 10MM
5.3. Epidemiology Scenario: 10MM
5.4. U.S. Epidemiology Scenario
5.5. EU-5 Epidemiology
5.5.1. U.K. Epidemiology Scenario
5.5.2. Germany Epidemiology Scenario
5.5.3. France Epidemiology Scenario
5.5.4. Italy Epidemiology Scenario
5.5.5. Spain Epidemiology Scenario
5.6. Japan Epidemiology Scenario
5.7. China Epidemiology Scenario
5.8. Australia Epidemiology Scenario
5.9. India Epidemiology Scenario
6. Real-world Data & Real-world Evidence
7. Drug Development Landscape
7.1. Existing Key Drug Candidate Profiles/ Marketed Therapies
7.1.1. FRUZAQLA (fruquintinib) - Takeda
7.1.1.1. Product Description
7.1.1.2. Regulatory Milestones
7.1.1.3. Other Developmental Activities
7.1.1.4. Pivotal Clinical Trials
7.1.1.5. Ongoing Current Pipeline Activity
7.1.2. TUKSYA (tucatinib) - Genentech/Seagen
7.1.2.1. Product Description
7.1.2.2. Regulatory Milestones
7.1.2.3. Other Developmental Activities
7.1.2.4. Pivotal Clinical Trials
7.1.2.5. Ongoing Current Pipeline Activity
7.1.3. ENHERTU (trastuzumab deruxtecan) - AstraZeneca/Daiichi Sankyo
7.1.3.1. Product Description
7.1.3.2. Regulatory Milestones
7.1.3.3. Other Developmental Activities
7.1.3.4. Pivotal Clinical Trials
7.1.3.5. Ongoing Current Pipeline Activity
7.1.4. KEYTRUDA (pembrolizumab) - Merck
7.1.4.1. Product Description
7.1.4.2. Regulatory Milestones
7.1.4.3. Other Developmental Activities
7.1.4.4. Pivotal Clinical Trials
7.1.4.5. Ongoing Current Pipeline Activity
7.2. Competitive Analysis and Differentiation
7.3. Overview of Similar/Competing Drugs in Clinical Trials
7.4. Future Trends and Emerging Drugs
7.4.1. Favezelimab + pembrolizumab - Merck
7.4.1.1. Product Description
7.4.1.2. Clinical Development
7.4.1.3. Safety and Efficacy
7.4.2. LUMAKRAS (sotorasib) - Amgen
7.4.2.1. Product Description
7.4.2.2. Clinical Development
7.4.2.3. Safety and Efficacy
7.4.3. Onvansertib - Cardiff Oncology
7.4.3.1. Product Description
7.4.3.2. Clinical Development
7.4.3.3. Safety and Efficacy
7.4.4. Nibrozetone (RRx-001) - EpicentRx
7.4.4.1. Product Description
7.4.4.2. Clinical Development
7.4.4.3. Safety and Efficacy
8. Regulatory Strategy and Potential Challenges
8.1. Regulatory Pathways in Key Markets
8.2. Anticipated Regulatory Hurdles and Mitigation Strategies
8.3. Case Studies in Oncology Drug Regulation
8.4. Impact of Potential Changes to Regulatory Framework
9. Commercial Landscape
9.1. Market Size & Growth Rates
9.2. Key Approvals & Anticipated Loss of Exclusivity
9.3. PESTLE & Porter’s Five Forces Analysis
9.4. Market Shares, Positioning/Ranking
9.5. Market Drivers
9.6. Identification of Threats
9.7. Digital Evolution in Commercialization
10. Market Segmentation
10.1. Market by Treatment
10.1.1. Chemotherapy
10.1.2. Targeted Therapy
10.1.3. Radiation Therapy
10.1.4. Surgery
10.1.5. Immunotherapy
10.1.6. Embolization
10.1.7. Others
10.2. Market by Route of Administration
10.2.1. Oral
10.2.2. Parenteral
10.2.3. Others
11. Pricing, Reimbursement, and Access
11.1. Competitive Pricing Analysis
11.2. Reimbursement Landscape and Challenges
11.3. Strategies for Market Access and Equity
11.4. Patient Spending/Expenditure Analysis
12. Future Trends, Disruptions, and Opportunities
12.1. Analysis of Emerging Trends
12.2. Technological Impact
12.3. Impact of Potential Market Disruptors
12.4. Opportunities for Future Development and Expansion
12.5. Considerations for Investment Opportunities
13. Global Market Dynamics
13.1. Regional Regulatory Disparities
13.2. Cross-Border Partnership Strategies
13.3. Global Supply Chain Dynamics
13.4. Case Studies: Success and Failure in Global Markets
13.5. Strategies for Global Expansion and Localization
14. Company Profiles
14.1. AstraZeneca
14.2. Novartis Pharmaceuticals
14.3. Pfizer
14.4. Takeda
14.5. Bristol-Myers Squibb
14.6. Amgen
14.7. Mirati Therapeutics
14.8. Lyell Immunopharma
14.9. SOTIO Biotech
14.10. Baili Pharmaceutical
Chapter 2. Automotive Lighting Market – Executive Summary
Market Segmentation
- 2.1 Market Size & Forecast – (2024 – 2030) ($M/$Bn)
- 2.2 Key Trends & Insights
- 2.2.1 Demand Side
- 2.2.2 Supply Side
- 2.3 Attractive Investment Propositions
- 2.4 COVID-19 Impact Analysis
- 2.1 Market Size & Forecast – (2024 – 2030) ($M/$Bn)
- 2.2 Key Trends & Insights
- 2.2.1 Demand Side
- 2.2.2 Supply Side
- 2.3 Attractive Investment Propositions
- 2.4 COVID-19 Impact Analysis
- 2.1 Market Size & Forecast – (2024 – 2030) ($M/$Bn)
- 2.2 Key Trends & Insights
- 2.2.1 Demand Side
- 2.2.2 Supply Side
- 2.3 Attractive Investment Propositions
- 2.4 COVID-19 Impact Analysis